The ARID5B Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human HAP1 cell line, designed for loss-of-function analysis of the AT-rich interactive domain-containing protein 5B (ARID5B) gene. This polyclonal product provides a pool of edited cells suitable for pooled screening and population-level functional assays without clonal selection biases.
HAP1 is a near-haploid human adherent cell line originally derived from the male KBM-7 chronic myeloid leukemia line. Its near-haploid karyotype enables efficient single-allele gene disruption and is widely used for CRISPR-based genetic screens. The leukemia origin offers a relevant model for hematological malignancies and cancer research.
ARID5B encodes a transcription factor that binds AT-rich DNA motifs and regulates genes essential for development, stem cell maintenance, and differentiation. It functions downstream of TGF-beta and BMP signaling, interacting with SMAD3, and is activated by STAT3, integrating JAK-STAT and TGF-beta pathways. ARID5B forms complexes with chromatin regulators HDAC1, EZH2, and SMARCA4 (BRG1) and transcriptionally controls pluripotency factors OCT4 (POU5F1), NANOG, MYC, and adipogenic regulator PPARG.
Knockout of ARID5B in the HAP1 background provides a clean loss-of-function model for studying its roles in stem cell pluripotency, hematopoiesis, adipogenesis, and osteoblast differentiation, especially within the JAK-STAT and TGF-beta signaling contexts. This model is particularly useful for investigating ARID5B??s contribution to acute lymphoblastic leukemia, neuroblastoma susceptibility, and developmental disorders featuring intellectual disability and dysmorphic features.
Applications include functional genomics, CRISPR screens, transcription factor biology, cancer research, stem cell pluripotency studies, and adipogenesis research. Standard assays include Western blotting, RT-qPCR, RNA-seq, ChIP-qPCR, immunofluorescence, flow cytometry, co-immunoprecipitation, adipogenic differentiation, and migration/invasion assays. The cells are also suited for drug target discovery. For more information, contact Ascent Research.
